As of 2024-12-12, the Relative Valuation of EyePoint Pharmaceuticals Inc (EYPT) is (35.82) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.25 USD, the upside of EyePoint Pharmaceuticals Inc based on Relative Valuation is -534.1%.
The range of the Relative Valuation is (22.66) - (35.95) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 23.6x | 22.2x |
| Forward P/E multiples | 14.9x - 25.2x | 24.9x |
| Fair Price | (22.66) - (35.95) | (35.82) |
| Upside | -374.7% - -535.8% | -534.1% |
| Date | P/E |
| 2024-11-29 | -5.82 |
| 2024-11-27 | -5.95 |
| 2024-11-26 | -5.92 |
| 2024-11-25 | -6.07 |
| 2024-11-22 | -5.88 |
| 2024-11-21 | -5.49 |
| 2024-11-20 | -5.89 |
| 2024-11-19 | -6.06 |
| 2024-11-18 | -5.64 |
| 2024-11-15 | -6.03 |
| 2024-11-14 | -6.90 |
| 2024-11-13 | -7.07 |
| 2024-11-12 | -7.31 |
| 2024-11-11 | -7.89 |
| 2024-11-08 | -7.65 |
| 2024-11-07 | -7.62 |
| 2024-11-06 | -7.94 |
| 2024-11-05 | -7.63 |
| 2024-11-04 | -7.69 |
| 2024-11-01 | -7.93 |
| 2024-10-31 | -7.73 |
| 2024-10-30 | -7.54 |
| 2024-10-29 | -7.59 |
| 2024-10-28 | -7.97 |
| 2024-10-25 | -6.25 |
| 2024-10-24 | -6.29 |
| 2024-10-23 | -6.55 |
| 2024-10-22 | -7.07 |
| 2024-10-21 | -7.04 |
| 2024-10-18 | -7.27 |
| 2024-10-17 | -7.33 |
| 2024-10-16 | -7.42 |
| 2024-10-15 | -6.50 |
| 2024-10-14 | -6.69 |
| 2024-10-11 | -5.81 |
| 2024-10-10 | -5.42 |
| 2024-10-09 | -5.52 |
| 2024-10-08 | -5.58 |
| 2024-10-07 | -5.73 |
| 2024-10-04 | -5.67 |
| 2024-10-03 | -5.50 |
| 2024-10-02 | -5.40 |
| 2024-10-01 | -5.26 |
| 2024-09-30 | -5.25 |
| 2024-09-27 | -5.25 |
| 2024-09-26 | -5.31 |
| 2024-09-25 | -5.36 |
| 2024-09-24 | -5.48 |
| 2024-09-23 | -5.45 |
| 2024-09-20 | -5.86 |